Last Updated: August 3, 2026

Litigation Details for Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. (D. Del. 2021)

Docket 1:21-cv-00512 Date Filed 2021-04-09
Court District Court, D. Delaware Date Terminated 2022-08-08
Cause 35:1 Patent Infringement Assigned To Joshua D. Wolson
Jury Demand Plaintiff Referred To
Patents 12,005,042
Link to Docket External link to docket
Small Molecule Drugs cited in Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. (D. Del. 2021)

Last updated: July 29, 2026

Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. (1:21-cv-00512): Litigation summary, claims, and risk analysis

Executive summary

The docket entry 1:21-cv-00512 in the case styled Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. contains insufficient accessible case-text and disposition details to produce a complete, accurate litigation summary and analysis under a patent-focused framework. Without verifiable information on asserted claims/patents, causes of action, procedural posture (motions, orders), and any final outcome or settlement terms, a litigation risk or merits analysis would be incomplete.

What patents are at issue in Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. 1:21-cv-00512?

A litigation summary requires the specific asserted patent numbers and claim sets (or, if not patent-based, the exact statutory basis and theory). The provided case identifier alone is not enough to extract the operative pleading content and identify:

  • asserted patents (publication/patent numbers)
  • asserted claims and infringement theories
  • accused products and specific functionality mapped to claim elements
  • venue and jurisdictional basis for the claims

What would typically be listed in the operative complaint?

  • Patent-in-suit list with claim numbers
  • Infringement contentions framework (at minimum for patent cases)
  • Alleged infringement by specific software components, versions, or deployment artifacts
  • Damages theory (reasonable royalty, lost profits, willfulness, design around)

What is the procedural posture in 1:21-cv-00512 (motions, scheduling, and orders)?

To summarize posture, the docket needs:

  • whether there is an amended complaint
  • Rule 12 motions and outcomes
  • claim construction schedule and any Markman order dates
  • summary judgment motions
  • discovery disputes and protective order issues
  • trial date setting and later vacating/continuances
  • dismissal, voluntary dismissal, or final judgment entries

What procedural signals drive litigation risk?

  • Whether a Markman occurred and how the court construed key claim terms
  • Whether a motion to dismiss or 101/103/112 challenge succeeded
  • Whether summary judgment narrowed the case to a subset of claims
  • Whether the parties entered a dismissal “with prejudice” consistent with settlement

Has Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. been dismissed or settled?

A business-grade analysis requires the end-state:

  • final disposition (dismissal type, with/without prejudice, settlement-linked)
  • any consent judgment
  • any order approving settlement or referencing confidential terms
  • whether the case is stayed pending reexamination or IPR outcomes
  • whether parties stipulated to vacatur of any orders

Settlement terms that matter for licensing strategy

  • license scope (product families, geographic scope, term)
  • royalty base and rate structure
  • most-favored-nation or audit rights
  • covenant not to sue for present and future versions
  • dismissal of related actions and cross-claims
  • exclusivity or restrictions on enforcement

What do the court’s rulings imply for claim strength in 1:21-cv-00512?

Litigation-strength analysis needs ruling content:

  • outcomes of validity challenges (especially 101 subject matter eligibility)
  • indefiniteness or enablement holdings under 35 USC 112
  • infringement sufficiency findings
  • evidentiary rulings affecting damages proof (expert admissibility)
  • willfulness findings or stays tied to willfulness

Claim-scope implications

  • narrowing constructions often reduce infringement surface area
  • broad constructions increase settlement leverage and licensing addressability
  • 101 and 112 outcomes can terminate the case early or force redesign attempts

What is the Orange Book-style exclusivity analog in software IP cases (if relevant)?

If the dispute is not a traditional patent infringement case, litigation framing can differ. A comparable “exclusivity” concept in software disputes is usually:

  • cease-and-desist enforcement posture
  • injunction risk
  • contract obligations overriding patent remedies
  • consent or license-back terms

But a real analysis depends on the causes of action actually pled.

What generic entry risks exist after any dismissal or settlement in 1:21-cv-00512?

For patent cases, “generic entry” is analogous to:

  • commercial entry of non-infringing implementations
  • workarounds that avoid construed elements
  • design-around opportunities created by claim construction

This requires knowing:

  • the accused technical features
  • the claim elements that were the basis for infringement allegations
  • whether the court found non-infringement or validity failures
  • whether the settlement includes covenants not to sue for alternatives

How strong is the patent estate (or IP portfolio) behind Virtuozzo’s claims?

A patent-estate analysis requires:

  • number of patents asserted
  • assignees and ownership chain
  • remaining term based on earliest priority dates
  • prosecution histories that affect claim interpretation
  • enforcement history and outcomes in related litigation

Without asserted patent identifiers and claim mapping, the estate-strength rating cannot be grounded in facts.

Commercial exposure: what revenue or product-line risk does this litigation create?

Exposure analysis requires at least:

  • the accused products’ market relevance and versioning
  • whether injunction was sought and whether any interim relief was granted
  • whether damages seek royalties or lost profits tied to specific customers

None of those inputs are available from the case caption alone.

Key Takeaways

  • A complete litigation summary and patent-focused analysis for Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. (1:21-cv-00512) cannot be produced from the provided case identifier alone.
  • A business-grade assessment requires operative pleadings and docket dispositions: asserted patents/claims, motion outcomes, and any final judgment or settlement entry.
  • Without those docket facts, any statement about merits, validity, infringement, or settlement terms would not meet the “high-stakes R&D, licensing, litigation, regulatory, or investment” standard.

FAQs

  1. What patents were asserted in Virtuozzo (Cyprus) Limited v. Cloud Linux, Inc. 1:21-cv-00512?
  2. Did Cloud Linux challenge validity on 35 USC 101, 102, or 103 grounds in 1:21-cv-00512?
  3. Were there Markman claim construction rulings in 1:21-cv-00512, and what claim terms were construed?
  4. Was there an injunction request or interim relief granted in 1:21-cv-00512?
  5. Did the parties settle in 1:21-cv-00512, and what was the procedural end-state (dismissal type)?

References

  1. Not available from the provided input.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.